A Tirzepatide request needs a person who can say no

Can the clinician ask another question?

A form can start a conversation. It can't replace the information needed to decide whether treatment makes sense. The medical boards' telemedicine policy says a fixed questionnaire alone isn't enough. A clinician using an interactive assessment needs a way to ask more questions or fill gaps in the history.

That's a policy for medical boards, rather than one law covering every online visit. Still, it's a helpful question for a reader: can the person reviewing this request find out more? A review can end with further questions, another plan or no prescription.

Who is responsible, and where?

Remote care still has a location: where the patient is during the appointment. The clinician needs the appropriate license or permission to practise there, according to federal telehealth guidance. State rules vary. Seeing a service online doesn't establish that it can offer every treatment where you are.

I'd also want the clinician's name. For physicians, state medical boards publish license and disciplinary information, as the boards' consumer guide explains. What is public varies by state. Those records help check a physician's identity and status; they don't guarantee good care.

Which medicine is being discussed?

Mounjaro (tirzepatide) and Zepbound (tirzepatide) are FDA-approved products. Compounded Tirzepatide is not FDA-approved. FDA doesn't check a compounded medicine's safety, effectiveness or quality before marketing. Its compounding questions and answers explain the difference.

The old shortage doesn't give unlimited permission to make copies. FDA confirmed the Tirzepatide injection shortage was resolved in December 2024. Its temporary policy said it did not intend to take action over certain shortage-related violations. Those periods ended in 2025. These are dated events in FDA's policy record, rather than a reason to assume an offer is lawful today.

Section 503A's patient-specific compounding rules include a valid prescription for an identified patient. They also restrict making medicines that are essentially copies of commercially available drugs, either regularly or in excessive amounts. A change for that patient can fall outside the copying restriction if the prescriber determines it makes a significant difference compared with the commercially available drug. A prescription alone doesn't settle every requirement.

What happens after the first decision?

For any service, I'd keep three questions together:

• Who decides whether treatment fits my history?
• Which product is being considered, and why?
• Who answers if something changes afterward?

The Zepbound label's safety information shows why follow-up matters. Other medicines, pregnancy and planned procedures can affect a review. The first prescription leaves those questions just as important.